WO2026120530 - NLRP3 INHIBITOR FOR USE IN TREATING MYELOID DISEASES
National phase entry is expected:
Publication Number
WO/2026/120530
Publication Date
11.06.2026
International Application No.
PCT/IB2025/062426
International Filing Date
04.12.2025
Title **
[English]
NLRP3 INHIBITOR FOR USE IN TREATING MYELOID DISEASES
[French]
INHIBITEUR DE NLRP3 DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE MALADIES MYÉLOÏDES
Applicants **
NOVARTIS AG
Inventors
BEAULIEU, Valerie
CARREON, Daniel
GATLIK, Ewa
GONZALEZ-MAFFE, Juan
LI, Yutong
RAUCH, Philipp
SINGH, Arti
WOO, Janghee
Priority Data
63/728,851
06.12.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3031 | |
| EPO | Filing, Examination, Granting | 17617 | |
| Japan | Filing, Examination, Granting | 2587 | |
| South Korea | Filing, Examination, Granting | 2951 | |
| USA | Filing, Examination, Granting | 6990 |
Total:
33,176
Contact Us
Abstract[English]
The present disclosure relates to the field of pharmacy, particularly to a NLRP3 inhibitor, for use in treating myeloid diseases, in particular myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS), for the manufacture of a medicament for treating myeloid diseases, in particular myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS).[French]
La présente divulgation concerne le domaine de la pharmacie, en particulier un inhibiteur de NLRP3, destiné à être utilisé dans le traitement de maladies myéloïdes, notamment le syndrome myélodysplasique (SMD), la leucémie myélomonocytaire chronique (LMMC), l'hématopoïèse clonale de potentiel indéterminé (CHIP) et la cytopénie clonale de signification indéterminée (CCUS), pour la fabrication d'un médicament destiné au traitement de maladies myéloïdes, notamment le syndrome myélodysplasique (SMD), la leucémie myélomonocytaire chronique (LMMC), l'hématopoïèse clonale de potentiel indéterminé (CHIP) et la cytopénie clonale de signification indéterminée (CCUS).